Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Tarih
2013
Yazar
Williams, Michael E.
Drach, Johannes
Ramchandren, Radhakrishnan
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas E.
Besisik, Sevgi
Goy, Andre
Sinha, Rajni
Üst veri
Tüm öğe kaydını göster
Özet
Purpose
Bağlantı
http://hdl.handle.net/20.500.12627/104713
https://doi.org/10.1200/jco.2013.49.2835
Koleksiyonlar